Yuhan Corporation (000100.KS) has secured another global active pharmaceutical ingredient (API) supply contract. The expanded production capacity of Yuhan Chemical, the subsidiary in charge of overseas API operations, is being credited with driving the string of new orders.
Yuhan Corporation said in a regulatory filing Thursday that it had signed an API supply contract with global pharmaceutical company Gilead Sciences. The contract is valued at $139.81 million (approximately 210.2 billion won). The indication for the drug to be supplied was not disclosed.
Yuhan has been securing large-scale API supply contracts in succession. In September 2024 and May 2025, the company signed contracts to supply APIs for human immunodeficiency virus (HIV) treatments worth a combined 196.5 billion won. In August last year, it won API supply contracts for AIDS and hepatitis C treatments worth 84.3 billion won and 85 billion won, respectively. All of these orders were for global pharmaceutical company Gilead.
Earlier this month, the company signed a 56 billion won API supply contract with U.S.-based BridgeBio Pharma for a cardiomyopathy treatment. Including the latest Gilead contract, cumulative orders over the past two years amount to approximately 632 billion won.
Yuhan Corporation's overseas API business is run by its subsidiary Yuhan Chemical. The latest order is interpreted as the visible result of years of investment and expansion in production facilities. Yuhan Chemical completed the expansion of the HB Building at its Hwaseong plant in April last year, securing total production capacity of 995,000 liters. Driven by the resulting growth in orders, Yuhan Chemical's revenue last year reached 289.7 billion won, up 36.5% from 2024.
